Mereo BioPharma Group (MREO) Business Model - Discounting Cash Flows
Mereo BioPharma Group plc
MREO (NASDAQ)

Industry

Biotechnology

Sector

Healthcare

Number of Employees

33
Mereo BioPharma Group's Business Model

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

About Mereo BioPharma Group

Website: https://www.mereobiopharma.com

CEO (Chief Executive Officer): Dr. Denise Vera Scots-Knight Ph.D.

IPO date: 2019-04-24

Contact

Country: GB

Address: One Cavendish Place

City: London

State: None

Phone: 44 33 3023 7300

Zip Code: W1G 0QF

Other

CIK: 0001719714

ISIN: US5894921072

CUSIP: 589492107

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us